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Abstract
Background: The receptor tyrosine kinase-like orphan receptors (ROR) family contains the atypical member ROR1,
which plays an oncogenic role in several malignant tumors. However, the clinical potentials and underlying
mechanisms of ROR1 in gastric cancer progression remain largely unknown. In this study, we validated the
microRNA-mediated gene repression mechanism involved in the role of ROR1.
Methods: Bioinformatic prediction, luciferase reporter assay, quantitative real-time PCR (qRT-PCR) and western
blotting were used to reveal the regulatory relationship between miR-27b-3p and ROR1. The expression patterns of
miR-27b-3p and ROR1 in human gastric cancer (GC) specimens and cell lines were determined by microRNA RT-PCR
and western blotting. Cell proliferation, colony formation assay in soft agar in vitro and tumorigenicity in vivo were
performed to observe the effects of downregulation and upregulation miR-27b-3p expression on GC cell phenotypes.
Results: miR-27b-3p suppressed ROR1 expression by binding to the 3’UTR of ROR1 mRNA in GC cells. miR-27b-3p
was significantly downregulated and reversely correlated with ROR1 protein levels in clinical samples. Analysis of
the clinicopathological significance showed that miR-27b-3p and ROR1 were closely correlated with GC characteristics.
Ectopic miR-27b-3p expression suppressed cell proliferation, colony formation in soft agar, xenograft tumors of GC cells.
By contrast, miR-27b-3p knockdown enhanced these malignant behaviors. Our studies further revealed that the c-Src/
STAT3 signaling pathway was involved in miR-27b-3p-ROR1-mediated cell proliferation regulation.
Conclusions: These results show that miR-27b-3p suppresses ROR1 expression through the binding site in the 3’UTR
inhibiting the cell proliferation. These findings indicate that miR-27b-3p exerts tumor-suppressive effects in GC through
the suppression of oncogene ROR1 expression and suggest a therapeutic application of miR-27b-3p in GC.
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Background
Gastric cancer (GC) is one of the most common solid
malignancies and a leading cause of cancer-related death
worldwide [1–6]. In China, GC is the second most diag-
nosed cause of cancer-related death [7]. Despite great
advancements in diagnosis and treatment for this dis-
ease, especially surgery, chemotherapy and radiotherapy,
the survival remains pessimistic [8]. Accordingly, new
clinically applicable molecular targets remain to be dis-
covered for the diagnosis and treatment of GC. The car-
cinogenesis, development, invasion and metastasis of
GC relate to a multi-step and multi-factor complex
process, and dysregulation of gene functions participate
in this process [4, 9]. Therefore, the identification of
novel and specific biomarkers with clinicopathologic and
prognostic significance in GC is important.
The receptor tyrosine kinase like orphan receptor 1
(ROR1) is a transmembrane protein that belongs to the
receptor tyrosine kinase family. ROR1 consists of an
extracellular frizzled-like, cysteine-rich domain, an extra-
cellular, membrane proximal kringle domain and an
intracellular tyrosine kinase like domain [10–12]. ROR1
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protein is evolutionarily conserved among various spe-
cies and it is primarily expressed during embryogenesis.
The deficiency of ROR1 mice do not display any mor-
phological abnormalities of the skeleton or heart or face,
but they die within 24 h after birth probably because of
respiratory failure [13, 14]. An increasing number of
studies indicated that ROR1 is highly associated with hu-
man cancers; however, the biological function of ROR1
remains to be assessed [12, 15–18]. ROR1 may serve
as a potential target for cancer therapy [11, 19], and a
tumor promoter in a variety solid malignancies, such
as breast, lung, ovarian neoplasms. [16, 17] The previous
study showed that ROR1 exhibited differential expres-
sion between human gastric carcinomas and corre-
sponding normal tissues [20]. These findings indicated
that the ROR1 gene might function as an oncogene, but
the mechanism by which ROR1 was regulated in GC
had yet to be clearly defined. c-Src is one of the most
well-characterized protooncogenes and non-receptor
protein tyrosine kinases, of which activation is a critical
event in the tumorigenesis of a large number of human
malignancies, including colon, gastric, breast, lung and
prostate cancer [21–23]. Once activated, c-Src is in-
volved in the regulation of normal and oncogenic pro-
cesses including proliferation, differentiation, survival
motility and angiogenesis [21]. c-Src has been shown to
interact with several proteins including receptor tyrosine
kinases, such as ROR1; and it has previously been dem-
onstrated that ROR1 could enhance the phosphorylation
of c-Src; other interaction partners with c-Src, including
signal transducers and activators of transcription (STATs),
heterotrimeric G proteins, the mitogen-activated protein
kinase ERK2, cyclin D, cyclin E and FAK, are important in
the cell proliferation and cell cycle regulation [18, 21, 24].
Previous studies suggest that ROR1 tightly involved in cell
growth and apoptotic signaling pathways.
MicroRNAs (miRNAs) are highly conserved endogen-
ous small 20–25 nucleotide non-coding RNAs [25, 26].
More than 50 % of the known miRNAs have been shown
to participate in human tumorigenesis and/ or metasta-
sis by directly targeting oncogenes or tumor suppressor
genes [27, 28]. It is becoming increasingly evident that
miRNAs play important roles in the regulation of cell
proliferation, apoptosis, migration and invasion thereby
affecting normal cell growth and development and
leading to a variety of disorders including malignancies
[29–31]. Emerging evidences have shown that miRNAs
can function as tumor suppressors or stimulators in the
tumorigenesis and progression of various human can-
cers, including gastric cancer [32]. For example, miR-
451, miR-101, let-7 and miR-17-92 have been reported
to regulate the proliferation, invasion and metastasis of
tumor cells by targeting some genes [33–35]. Given
that miR-27b has been reported to be downregulated
and implicated in suppressing invasion, metastasis in
gastric cancer [36]. To the best of our knowledge, lim-
ited information is obtainable concerning the clinical
potentials and underlying mechanisms of miR-27b-3p
in GC thus far. In the current work, we validated that
the 3’UTR of ROR1 contains a highly conserved miR-
27b-3p binding motif and its direct interaction with
miR-27b-3p downregulated endogenous ROR1 protein
level. Therefore, this study aimed to investigate the
antitumor effect of miR-27b-3p and its correlation with
ROR1 in GC cells. We demonstrated the expression of
ROR1 and miR-27b-3p in GC cells, validated the rela-
tionship between ROR1 and miR-27b-3p, and explored
the role of the miR-27b-3p-ROR1 axis in GC cancers.
The data showed that miR-27b-3p suppresses cell
proliferation by inducing G0/G1 phase arrest mainly
through targeting ROR1. Our study is the first report
showing the role of miRNA-27b-3p in the regulation of
ROR1 expression in GC cells. The results identifying a
new tumor-suppressive miR-27b-3p-mediated pathway
in GC and provide new insights into the pathogenesis
of gastric oncogenesis and will aid the development of
novel therapeutic strategies.
Methods
Patients and cell lines
The paired tumorous and adjacent non-tumorous hu-
man gastric tissues, were obtained from 56 patients with
gastric cancer who underwent radical resection in Affili-
ated People’s Hospital of Jiangsu University. All patients
were diagnosed pathologically according to the criteria
of the American Joint Committee on Cancer by two pro-
fessional pathologists independently. All patients gave
their informed consent and the study was approved by
the institutional ethics committee of Jiangsu University.
Written informed consents were obtained before speci-
men collection. The human GC cell lines MGC803, AGS,
MKN45, MKN28, SGC7901, HGC27, NCI-N87 and
BGC823, and normal human gastric epithelial cells
(GES-1) used in this study were obtained from the
Chinese National Human Genome Center at Shanghai.
Immunohistochemistry
MaxVisionTM techniques (Maixin Bio, China) were
used for immunohistochemistry (IHC) analysis, accord-
ing to the manufacturer’s instructions. After blocking
the endogenous peroxides and proteins, 4 μm sections
were incubated overnight at 4 °C with diluted primary
antibodies specific for ROR1 (Abcam). Next, the slides
were incubated with an HRP-Polymer-conjugated sec-
ondary antibody at 37 °C for 1 hour. The slides were
then stained with a 3,3-diaminobenzidine solution for
3 min and counterstained with hematoxylin. Tumor
slides were examined in a blinded manner. Three fields
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were selected for examination, and the percentage of posi-
tive tumor cells and cell-staining intensity were determined.
Quantitative real-time PCR
Total RNA was extracted with the TRIzol reagent (Invitro-
gen) according to the manufacturer’s instructions, and
was reverse transcribed into cDNA using Primescript RT
Reagent (Takara). Real-time PCR was performed using a
7500 Real-time PCR System (Applied Biosystems) with
SYBR Premix Ex Taq Kit (Takara). The following primers
were used: ROR1, forward: 5’-CAGTCAGTGCTGAAT-
TAGTGCC-3’, reverse: 5’-TCATCGAGGGTCAGGTAA-
GAAT-3’; β-actin, forward: 5’-AGAGCCTCGCCTTTGC
CGATCC-3’, reverse: 5’-CTGGGCCTCGTCGCCCACAT
A-3’. All procedures were performed in triplicate.
Luciferase reporter assay
The 3’UTR of ROR1 containing the wild or mutated miR-
27b-3p binding sequences were synthesized by Genescript
(Nanjing, China). The sequences were cloned into pGL3
luciferase control reporter vector (Promega, USA) to gen-
erate the ROR1 3’UTR reporter. Total 5 × 105 cells were
seeded in 24-well plates. Cells were cotransfected with
0.12 μg of either pGL3-WT-ROR1 or pGL3-MUT-ROR1
3’UTR reporter plasmid together with 40 nM of miRNA
mimics or negative control oligoribonucleotides using
Lipofectamine 2000 (Invitrogen) following the manu-
facturer’s protocol. Firefly and Renilla luciferase activ-
ities were measured by Dual-Luciferase reporter assay
(Promega). All procedures were performed in triplicate.
miRNA RT-PCR
Total RNA was extracted as above. Target-specific re-
verse transcription and Taqman microRNA assay were
performed using the Hairpin-itTM miRNAs qRT-PCR
Quantitation Kit (Genepharma) according to the manu-
facturer’s instructions. The reactions were performed on
the 7500 Real-Time PCR System. The snRNA U6 was
selected as an endogenous reference to calculate the
relative expression levels of miR-27b-3p in every sample
using the 2-ΔΔCt method. All experiments were done in-
dependently in triplicate.
Vector construct, lentivirus production and cell
transfection
miR-27b-3p mimics and miR-27b-3p inhibitor were
packaged in lentiviral vector (Genepharma) to overex-
press or knockdown miR-27b-3p in GC cells. Lentiviral
vector (miR-NC) served as a negative control. The con-
structed vectors were verified by DNA sequencing.
When AGS and BGC823 cells grew to 50 % confluence,
cells were infected with lentiviral vectors miR-NC, miR-
27b-3p mimics or miR-27b-3p inhibitor, respectively, at
an appropriate multiplicity of infection. The above four
groups of cells AGS-NC, AGS-miR-27b-3p inhibitor,
BGC823-NC and BGC823-miR-27b-3p mimics were se-
lected with 3.5 lg/ml puromycin (Sigma) for 6 days to
build stable cell lines. Thereafter, the cells were analyzed
using Hairpinit TM miRNAs qRT-PCR Quantitation Kit
for miR-27b-3p expression. Stably infected cells were
selected for further experiments. The full-length ORF
of ROR1 (GeneBank accession no.: NM_005012.3) was
amplified from a human GC cell lines cDNA library.
The primers were as follows: forward, ROR1-XhoI-F:5’-
AGGCTCGAGATGCACCGGCCGCGCCGC-3’, ROR1-
HindIII-R:5’-AGGAAGCTTCAGTTCTGCAGAAATCA
TAGATTC-3’. The PCR product was inserted into the
expression vector pcDNA3.1B (Invitrogen). The oligonu-
cleotides encoding short hairpin RNAs (shRNA) were
synthesized and inserted into pSUPER vector, and desig-
nated pSUPER-shNC-vector (vector), pSUPER-sh-ROR1











Cells (2000/well) were seeded into 96-well plates and
stained at the indicated time point using the Cell Count-
ing Kit-8 (Dojindo Laboratories), according to the in-
structions of the manufacturer’s instructions. The optical
density measured at 450 nm was used as an indicator of
cell viability.
Colony formation assay
To examine the effect of upregulated or downregulated
cortactin expression on proliferation of colon cancer cell
lines, cells transfected with different plasmids were used
for the colony formation assay. Each type of cell was
seeded into 24-well plates (50,000 cells/well) and cultured
for 3 weeks in medium containing 1,000 μg/ml G418.
These cultures were stained with 0.4 % crystal violet.
Clones > 2 mm were counted and the number of clones
per well was averaged from three wells for each experi-
ment. Each experiment was repeated at least 3 times.
Soft agar colony formation assay
The soft agar assay was performed, to evaluate anchorage
independent growth. GC cells were resuspended in 0.5 ml
1 % low-melting-point agarose with complete culture
medium, and layered on top of 0.5 ml 2 % lowmelting
agarose in 24-well plates (2,000 to 5,000 cells/well). The
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plates were incubated at 37 °C in a humidified atmosphere
of 5 % CO2 for 2 weeks. Colonies containing at least 50
cells were counted [37]. All experiments were repeated
three times.
Cell cycle assay
Flow cytometry was used to analyze the cell cycle. First,
cells were cultured in serum-free medium for 24 h to in-
duce cell cycle synchronization. Cells were harvested at
a different time point. For DNA content analysis, cells
were fixed in 70 % ethanol, rehydrated in PBS, treated
with RNase A (10 mg/ml) for 30 min then stained with
propidium iodide (10 μg/ml) for 5 min.
Tumor xenografts in vivo
Approximately 4-6 × 106 GC cells were injected subcuta-
neously into the flank of male nude mice (4 weeks old).
Tumors were measured and weighed 4 weeks after
injection. Tumor size was measured with calipers every
3 days, and tumor volume was determined using the fol-
lowing formula: Tumour volume = (width2 × length)/2.
Immunoblotting
Cell extracts were collected in a lysis buffer (50 mM
Tris–HCl [pH 7.4], 150 mM NaCl, 1 % Triton X-100,
0.1 % SDS, 1 mM EDTA and protease inhibitor cocktail).
The cellular protein was size-fractionated by SDS–poly-
acrylamide gel electrophoresis and transferred to PVDF
membranes (Bio-Rad Laboratories). After blocking with
PBS containing 5 % BSA, the membrane was incubated
with the appropriate primary antibody at 4 °C overnight,
followed by incubation with HRP-conjugated anti-
mouse or antirabbit IgG at room temperature for 2 h.
The protein bands were detected using an enhanced
chemiluminescence (ECL) detection system following
the manufacturer’s instructions. The following primary
antibodies were used: anti-ROR1 (abcam), anti-c-Src
(santa), anti-p-c-Src (santa), anti-STAT3, anti-p-STAT3,
anti-cyclinD, anti-c-Myc and anti-GAPDH (cell signal-
ing technology). All procedures were performed in
triplicate.
Statistics
All experiments were repeated in triplicate in this article.
Statistical analysis was performed with SPSS software.
Data were analyzed using two-tailed Student’s t-tests.
Categorical data were evaluated by the χ2 test. Analysis
of variance (ANOVA) was used to compare the control
and treated groups. P-values <0.05 were considered sta-
tistically significant.
Results
ROR1 is dysregulated in human gastric cancer tissues and
cells
The expression level of ROR1 was analysed in 56 paired
human GC specimens by using real-time PCR. It was
shown that the upregulation of ROR1 was significant in
the GC tissues compared to the paired adjacent non-
tumor samples (Fig. 1a). Furthermore, the expression
level of ROR1 in GC cell lines and a normal human gas-
tric mucosal cell line was validated by qRT-PCR (Fig. 1b).
We also assessed the protein level of ROR1 in six paired
tissues of typical cases by western blotting (Fig. 1c). To
further confirm the expression levels of ROR1 in tumor
cells, IHC analyze for tumors was employed. The results
showed that the expression of ROR1 protein was either
high or low in tumor cells, while the ROR1 protein in
normal mucosal cells was rarely expressed (Fig. 1d). Fur-
thermore, the correlation between ROR1 or miR-27b-3p
expression levels and clinicopathological features were
assessed. The patients were split into two groups based
on our real time PCR results for ROR1: high expression
(+) and low expression (−). It was shown in Table 1 that
those patients with tumor size larger than 3 cm had a
significantly higher expression of ROR1 than those pa-
tients with tumor size smaller than 3 cm. In addition,
the expression level of miR-27b-3p was lower in samples
with tumor size larger than 3 cm and stages III/IV.
ROR1 knockdown inhibits cell proliferation and induces
cell cycle arrest
pSUPER-sh-NC-vector (vector) and pSUPER-sh-ROR1
(sh-ROR1) were built in order to knockdown endogen-
ous ROR1 in BGC823 cell line. qRT-PCR was used to
determinate the expression of ROR1. CCK-8 assay and
colony formation were used to evaluate proliferative
ability. Flow cytometry was used to measure cell cycle
distribution. The expression of ROR1 was downregu-
lated by sh-ROR1 transfection (Fig. 2a). Further, ROR1
knockdown suppressed cell proliferative viability (Fig. 2b
and c). In addition, ROR1 knockdown induced G0/G1
phase arrest (Fig. 2d). These data suggest that thera-
peutic ROR1 knockdown may favor the prognosis of GC
patients.
ROR1 is a direct downstream target of miR-27b-3p
Previous study suggested that ROR1 is highly upregulated
in GC tissues led us to explore the mechanism of ROR1
overexpression [18]. To investigate whether the expression
of ROR1 is regulated by miRNAs, TargetScan (http://
www.targetscan.org/), PicTar (http://pictar.mdc-berlin.de/)
and miRanda (http://www.microrna.org/microrna/home.do)
were used in combination to predict miRNAs which might
target ROR1. As shown in Fig. 3a, we found that
miR-27b-3p can bind the 3’UTR of ROR1. The luciferase
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valueHigh Low High Low
(n = 34) (n =22) (n = 15) (n = 41)
Age (year)
<60 14 10 6 19
≥60 20 12 0.788 9 22 0.767
Gender
Male 19 14 8 15
Female 15 8 0.592 7 26 0.359
Tumour size (cm)
<3 12 16 9 11
≥3 22 6 0.013* 6 30 0.030**
Differentiation
Well 10 9 10 22
Moderately and poorly 24 13 0.401 5 19 0.544
Stage
I + II 13 7 8 9
III+ IV 21 15 0.777 7 32 0.046*
*P < 0.05 Statistically significant difference
Fig. 1 The expression of ROR1 in GC cells. a ROR1 mRNA expression in 56 pairs of human GC and their corresponding non-tumour samples. b
ROR1 mRNA was evaluated in eight GC cell lines and normal human gastric epithelial cells. c The protein levels of ROR1 in six paired GC tissues
were detected by western blotting. d Representative results of the upregulation of ROR1 protein in GC specimens by immunohistochemistry
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reporter assay was employed to validate the hypothesis.
Wild-type and mutant ROR1 3’UTR containing putative
target sites of miR-27b-3p were cloned into reporter plas-
mids respectively. The results revealed that the activity of
the luciferase reporter gene fused to the ROR1 3’UTR was
significantly declined by miR-27b-3p. Luciferase respon-
siveness to miR-27b-3p was abrogated because of the mu-
tation of the putative miR-27b-3p binding sites in the
3’UTR of ROR1 (Fig. 3c). Western blotting showed that
ROR1 protein levels were inhibited in miR-27b-3p mimics-
transfected cells (Fig. 3b). Furthermore, we confirmed that
miR-27b-3p was significantly downregulated in GC and
GC cell lines (Fig. 3d and f), notably, by analyzing of their
expression levels in GC tissues, the expression level of
miR-27b-3p was found to be negatively associated with
ROR1 mRNA expression (Fig. 3e). In summary, ROR1may
be as an oncogene accelerator in GC.
miR-27b-3p suppressed cell proliferation and induce cell
cycle arrest mainly by targeting ROR1 in vitro
To determine the role of the direct interaction between
miR-27b-3p and ROR1, western blotting was used. As
Fig. 2 ROR1 regulates cell proliferation, colony formation and cell cycle in vitro. a and b Cells were transfected with vector and sh-ROR1, and the
knockdown efficiencies of sh-ROR1 in BGC823 cell were measured by RT-PCR, and the different symbols represent the corresponding mean values
of the experiments, performed in triplicate (mean ± SD), P < 0.05 was calculated on days 4, 5 and 6; c Knockdown of ROR1 inhibits colony formation of
BGC823 cells. d The effect of ROR1 on cell cycle
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shown in Fig. 4a, miR-27b-3p could inhibit the protein
levels of ROR1 in BGC823 cell line. In contrast, the
miR-27b-3p inhibitor upregulated ROR1 protein levels
in AGS cell line. Furthermore, cell proliferation was
measured by the CCK-8 and colony formation in soft
agar assay, and miR-27b-3p significantly suppressed cell
proliferation in BGC823 cell line, whereas miR-27b-3p
inhibitor enhanced cell viability and colony formation
(Fig. 4b and c). In addition, flow cytometry indicated
similar cell cycle distribution in cells with overexpression
of miR-27b-3p through induction of G0/G1 phase arrest.
miR-27b-3p inhibitor was further used in AGS cell, the
results showed that miR-27b-3p is downregulated by
specific inhibitors, along with cell cycle progression
(Fig. 4d). To further illustrate miR-27b-3p that affects
cell proliferation by regulating ROR1, we investigated
whether ROR1 counteracted the suppression of cell
phenotypes caused by miR-27b-3p overexpression in GC
cells. The vector ROR1, which contains only the ROR1
coding sequence, was constructed for ROR1 expression
without miR-27b-3p targeting. BGC823 cells were
cotransfected with miR-27b-3p mimics and either ROR1
Fig. 3 ROR1 is a direct downstream target gene of miR-27b-3p. a The ROR1 3’UTR regions containing the wild-type or mutant binding site for
miR-27b-3p are shown. b Western blotting was used to analyze the expression levels of ROR1 after transfecting with miR-NC or miR-27b-3p
mimics. c Relative ROR1 luciferase activity was analyzed after the wild-type or mutant 3’UTR reporter plasmids co-transfected with miR-NC or
miR-27b-3p. d RT- PCR was used to detect the expression levels of miR-27b-3p in GC and non-GC specimens. e The scatter plots show the
expression levels of miR-27b-3p and ROR1 in GC samples. Linear regression analysis was used to measure the association between miR-27b-3p
and ROR1. f The expression of miR-27b-3p in a panel of tumorigenic GC cell lines
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Fig. 4 miR-27b-3p inhibits GC progression in vitro. a Western blotting assay was used to analyze the expression levels of ROR1 and miR-27b-3p
in AGS and BGC823 cells transfected with miR-NC, miR-27b-3p inhibitor or miR-27b-3p mimics; b Representative profiles of CCK-8 cell growth in
AGS cells after transfection with miR-27b-3p inhibitor compared to the miR-NC, transfection with miR-27b-3p mimics inhibited cell proliferation
compared with miR-NC used as control. c Effects of miR-27b-3p on the colony formation of GC cells. The number of colonies was calculated and
analyzed. d The effects of miR-27b-3p on cell cycle
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or pcDNA3.1B empty vector. The data clearly confirmed
that ectopic expression of ROR1 partly reversed the sup-
pression of cell proliferation and cell cycle arrest caused
by miR-27b-3p overexpression (Fig. 5a, b and c). These
data collectively indicated that miR-27b-3p inhibits cell
proliferation and induces cell cycle arrest mainly by tar-
geting ROR1, and that miR-27b-3p may act as a “tumor
suppressor” in GC.
miR-27b-3p influences tumorigenesis and tumor burden
The effects miR-27b-3p on the tumourigenic potential of
GC cells in vivo were also evaluated. Compared with
AGS cells transfected with miR-NC, injection of the
same cells transfected with miR-27b-3p-inhibitor re-
sulted in larger tumors sizes in male nude mice about
4 weeks after injection (Fig. 6a, c and d). To determine
the effect of overexpression of miR-27b-3p on tumori-
genicity in vivo, miR-27b-3p mimics was used to trans-
fect BGC823 cells, then these cells were harvested and
injected into the flank of male nude mice. As expected,
miR-27b-3p mimics was able to significantly suppress
tumorigenicity, resulting in obvious reductions in tumor
weight and volume compared to miR-NC (Fig. 6b, c and d).
All these data indicate that miR-27b-3p mediated ROR1
plays a key role in GC tumorigenesis.
miR-27b-3p mediated differential expression of ROR1
affects the c-Src/STAT3 signaling pathway related
proteins
To further study the mechanism by which miR-27b-3p
mediated ROR1 enhances the growth of GC, the c-Src,
p-c-Src, STAT3, p-STAT3, c-Myc and cyclin D1 protein
levels were detected by western blotting. The levels of
p-c-Src, p-STAT3, c-Myc and cyclin D1 were shown to
be significantly upregulated in AGS cell line transfected
with miR-27b-3p-inhibitor compared with the same
cells transfected with the miR-NC, however, no differ-
ence in the total c-Src and STAT3 protein levels were
Fig. 5 miR-27b-3p inhibits GC progression by mainly downregulating ROR1 in vitro. a Cells were transfected with miR-NC, miR-NC + pcDNA3.1B,
miR-27b-3p mimics + pcDNA3.1B, miR-27b-3p mimics + ROR1, respectively, and cell viability was measured by the CCK-8 assay at 1 d, 2 d, 3d, 4d,
5d and 6d; b and c Cell cycle distribution was determined by flow cytometry analysis. Mean ± SD, *p < 0.05
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observed between the two cell groups. As expected, a
reduction in the level of p-c-Src, p-STAT3, c-Myc and
cyclin D1 protein in BGC823 was caused by the miR-
27b-3p mimics compared with the negative control,
likewise, the level of total c-Src and total STAT3 ex-
pression were found to be almost unchanged (Fig. 6e).
These data indicate that miR-27b-3p mediated differen-
tial expression of ROR1consequently resulted in activa-
tion of c-Src/STAT3 signaling pathway.
Discussion
Although there is extensive information from the past
about gastric cancer at genetic and molecular level,
differing clinical courses and the limited value of estab-
lished prognostic markers have compelled researchers to
look for new molecular parameters in predicting the
prognosis and treatment of patients with GC. Identifying
appropriate molecular targets and understanding the
molecular basis of these pathways is an important step.
Recently, aaccumulating evidence suggests that the
aberrant miRNAs expression signature is a hallmark of
malignancies, it also has been reported that miRNAs
play important roles in regulating diverse cellular pro-
cesses including proliferation, apoptosis, migration and
invasion [29–31, 38]. We can infer that, to date, the
mechanism by which miRNA exerts its function is still a
topic of great interest in cancer biology. Although many
studies have reported the role of miR-27b in cancer pro-
gression, much remains to be illuminated to supplement
the network of its interactions, a series of comprehensive
research data have identified miR-27b as a tumor
suppressor in a series of malignant tumor [36, 39, 40].
Fig. 6 miR-27b-3p inhibits xenograft tumor growth of GC cells. a and b Photographs of tumors derived from the different groups of nude mice;
the graph is representative of tumor growth 21 days after inoculation. c and d Tumor volume and the weight were calculated, and all date are
shown as mean ± SD (* P < 0.05). e Western blotting analysis of c-Src/STAT3 signaling pathway related proteins showed upregulation of p-c-Src,
p-STAT3, c-Myc and cyclin D1 in miR-27b-3p inhibitor of AGS cell and downregulation of p-c-Src, p-STAT3, c-Myc and cyclin D1 in miR-27b-3p
mimics of BGC823 cell, total c-Src and total STAT3 protein level was unchanged
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However, limited information is obtainable concerning
the clinical potentials and underlying mechanisms of
miR-27b-3p in GC thus far. Herein, we demonstrated
that miR-27b-3p could regulate cell proliferation, colony
formation and tumorigenicity by targeting oncogene
ROR1 in GC. In our previous study, we used bioinfor-
matics software to predict the candidate miRNAs target-
ing ROR1. Bioinformatic prediction, luciferase reporter
assay, qRT-PCR and western blotting were used to reveal
the regulatory relationship between miR-27b-3p and
ROR1. In this study, our data also demonstrated that
miR-27b-3p could repress ROR1 protein expression in
GC cells. Furthermore, compelling evidences proved that
miR-27b-3p was significantly downregulated and re-
versely correlated with ROR1 protein levels in clinical
samples. Herein, our findings conclude that ROR1 could
be a new target gene of miR-27b-3p in GC.
ROR1 is a member of the RORs family which consists
of ROR1 and ROR2. RORs contain two distinct extra-
cellular cysteine rich domains and one transmembrane
domain. RORs are transmembrane proteins which are
members of the receptor tyrosine kinase family. The
intracellular part of ROR1 possesses a tyrosine kinase
domain, two serine/threonine-rich domains and a
proline-rich domain [10, 41]. The ROR1 is shown to
play a role in tumor-like behavior, such as cell migra-
tion and cell invasiveness and are negatively expressed
in normal adult tissue, ROR1 has recently been found
to be expressed in human cancers, and have the poten-
tial to be cancer targets [11, 17]. Ectopic expression of
ROR1 is also observed in a wide variety of solid malig-
nancies, tissue microarray analysis showed strong stain-
ing of ROR1 in 30 % or greater of primary samples in
colon, lung, and pancreatic cancers [16]. However,
moderate staining is detected in the majority of ovarian,
lymphoma, skin, testicular, uterine, prostate, and ad-
renal cancers [16]. In this study, ROR1 was identified
as an important downstream target of miR-27b-3p.
Overexpression of miR-27b-3p significantly reduced the
ROR1 level in GC cells, and the inhibitory effects of
miR-27b-3p on GC cell proliferation and colony forma-
tion were reversed by overexpression of ROR1. Further-
more, ROR1 was increased in GC tissues and negatively
correlated with the expression of miR-27b-3p. Taken
together, these results indicated that miR-27b-3p might
suppress cell proliferation through targeting ROR1.
c-Src is one of the most well-characterized protoon-
cogenes and non-receptor protein tyrosine kinases. In
fact, c-Src is known to be overexpressed and/or hyper-
activated in a wide variety of human cancers, such as
colon, gastric and prostate cancer [22, 23, 42]. c-Src
plays a role as transcriptional regulator and enhances
carcinogenesis via regulating a series of downstream
target genes. However, the biological effects of this gene
in GC development have are still unclear.
Recently c-Src has been identified as a substrate gene
of ROR1, which is capable of interacting with c-Src and
control c-Src-mediated transformation, and could fur-
ther participate in neoplastic transformation and con-
tribute to tumorigenesis [24, 43]. This result suggests
that ROR1 may promotes the proliferation of cancer
cells through c-Src activation. The signal transducer
and activator of transcription family was important for
promoting the proliferation, survival and other bio-
logical processes triggered by cytokines and growth fac-
tors [44–47]. Although there are seven STAT proteins,
Fig. 7 Schematic miR-27b-3p inhibits GC cell proliferation through ROR1 suppression.
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STAT3 is the most important downstream molecule for
c-Src kinase [48–50]. The increased protein level of
phosphorylation c-Src (p-c-Src) in gastric cancer cell
caused by ROR1 was identified in this study. Given that
ROR1 can enhance the phosphorylation of c-Src, other
downstream target genes which include STATs, hetero-
trimeric G proteins, the mitogen-activated protein kin-
ase ERK2, cyclin D, cyclin E, c-Myc and FAK, are the
important key point in the cell proliferation [18, 21, 24].
Therefore, the relationship between ROR1 expression in
GC cells and cell cycle was analyzed. We found that
ROR1 promotes phase transition of GC cells into S phase
from G0/G1 phase. It has been reported in several studies
that regulation of G1/S phase transition is often abnormal
in cancer cells, with the cyclins or CDK proteins and their
upstream regulators changed accordingly [51–54]. Cyclin
D1 is the major cyclin regulating cell cycle transition from
G0/G1 phase to S phase [55, 56]. In this study, our data
indicate that ROR1 is the main downstream target gene of
miR-27b-3p, and that miR-27b-3p can bind to its
3’UTR and subsequently regulate its expression post-
transcriptionally. Re-expression ROR1 upon miR-27b-3p
overexpression could partly reverse but not completely
prevent the effect of miR-27b-3p. Thus, miR-27b-3p add-
itionally suppresses cell proliferation via interactions with
other target genes, although miR-27b-3p suppresses cell
proliferation and induces G0/G1 cell cycle arrest by
mainly targeting ROR1.
Conclusions
In conclusion, the present study provides evidence that
the dysregulation of ROR1 results from miR-27b-3p
downregulation in GC and may promote cancer progres-
sion, and the c-Src/STAT3 signaling pathway was in-
volved in miR-27b-3p-ROR1-mediated cell proliferation
regulation (Fig. 7). Therefore, this study demonstrates a
novel regulator of ROR1 and enriches our knowledge on
the interactions between miR-27b-3p and its targets in
GC. Thus, our findings provide new prospects for miR-
27b-3p and ROR1 as promising molecular therapies in
GC treatment.
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